We investigated factor VIII (FVIII) gene mutations in 20 thrombosis patients with high level of FVIII and 20 control healthy participants. Blood samples were used for the determination of FVIII levels using static timing analyze (STA) kits. Informed consent forms were collected from all participants. Factor VIII level was 237 + 46 IU/dL in patients group; however, it was 122 + 38 IU/dL in healthy control participants. Isolated genomic DNAs were screened using 37 pairs of primers covering promoter region and 26 exons of FVIII gene. Single-strand conformation analysis (SSCA) technique was performed for polymorphism/mutation analyses. We observed polymorph patterns in exon 6, exon 13, exon 14F, exon 19, and exon 25 regions. However, we found no evidence of an association between observed single nucleotide polymorphisms and high thrombosis levels. In conclusion, observed exons polymorphisms do not seem to be associated with a venous thromboembolism.
Introduction
Inherited disorders related to hemostatic system are known as risk factors for thromboembolic events such as myocardial infarction, stroke, pulmonary embolism, pregnancy complications, and especially recurrent deep vein thrombosis (DVT). 1 High levels of factor VIII (FVIII) are a risk factor for thrombosis, with a greater impact on venous than on arterial thrombosis. This risk is dose dependent for venous thrombosis and FVIII levels more than 150 IU/dL account for 16% of all venous thrombosis events, whereas FVIII levels 123 IU/dL explain 4% of all arterial events. 2 High FVIII levels may increase the risk of venous thrombosis via enhanced thrombin formation and/or through the induction of acquired APC resistance. 2 The regulation of plasma FVIII levels is complex. Most FVIII circulates as a complex with von Willebrand factor (vWF) 3, 4 the levels of which are known to be dependent on factors such as blood group [5] [6] [7] and endothelial stimulation. 8, 9 This highly complicates the study of the molecular basis of elevated FVIII levels. The molecular basis of high FVIII levels is only partially known and consists of genetic and acquired factors. Blood group, acting through vWF levels, is an important genetic factor that explains 30% of the variation in FVIII levels. Attempts to find other genetic loci associated with high vWF and FVIII levels have failed until now. It is likely that the largest part of high FVIII levels is caused by a rise in vWF levels, which points to an increased synthesis or decreased clearance of the vWF-FVIII complex. 2 However, a substantial percentage of high FVIII levels is not completely vWF mediated and may point to genetically defined differences in the affinity of FVIII for vWF. There are some reports on sequence variations of the coagulation FVIII structural gene and associations with plasma FVIII activity levels. Recently, Viel et al 10 to determine whether FVIII gene is a determinant of FVIII variability resequenced all known functional regions within a collection of 222 X chromosomes from 137 unrelated participants and genotyped the polymorphisms identified in the 398 participants of the Genetic Analysis of Idiopathic Thrombophilia Project (GAIT) and suggested that 92714C>G, a nonsynonymous SNP encoding the B-domain substitution D1241E, was significantly associated with FVIII: C level. However, there is still the need to find out the variations in the FVIII gene in different populations. We conducted this study to determine the possible association between high levels of FVIII and name unknown nucleotide variations in FVIII gene itself in Turkish patients group with a history of venous thromboembolism in comparing with healthy control participants.
Methods
We enrolled 52 patients with objectively documented venous thromboembolism (pulmonary embolism and/or DVT) in this study. Blood samples were obtained from patients admitted to Istanbul University Medical Faculty, Hematology, General Surgery sections and vein polyclinics. The control group consisted of 20 healthy individuals (13 male, 7 female; mean age: 49 + 12 years). None of the control participants had a familial history of VTE and cardiopulmonary disease. This study was approved by the Institutional Review Board/Ethics Committee at Istanbul University, and all patients and controls provided written informed consent in accordance with the Declaration of Helsinki. Blood samples were used for the determination of FVIII levels using static timing analyze (STA) kits. We determined that only 20 patients (13 male, 7 female; mean age: 23 + 17 years) in 52 patients have elevated plasma levels of FVIII. Therefore, these 20 patients were included into the study for molecular genetic analysis. Polymerase chain reaction (PCR) 11 -based method was used to establish the single-strand conformation analyses (SSCA) 12 for mutation/polymorphism studies. Venous blood samples (5 mL) were collected in ethylenediaminetetraacetic Vacutainer from patients and control participants. Genomic DNA was extracted from peripheral blood leukocytes. Primers used in this study were given in Table 1 . Different SSCA products were investigated with direct DNA Sequencing Analysis System. Differences observed in DNA sequence analyses were compared in ExPASy (Expert Protein Analysis System) translate tool. 
Results
We observed single nucleotide polymorphisms in gene exons 6, 13, 14F, 19, and 25 of FVIII gene in 20 thrombosis Turkish patients with high level of FVIII in comparing with 20 control healthy participants using SSCA technique. Factor VIII levels of patients and control participants were 237 + 46 and 122 + 38 IU/dL, respectively. As it can be seen, FVIII levels almost doubled in thrombosis patients group comparing to the control participants. Polymerase chain reaction conditions with 37 designed primers were successfully achieved and were presented on Figure 1 . Two of the SSCA gel analyses studies were presented in Figures 2 and 3 . In Figure 2 , patient (no 8) has different pattern in FVIII gene 13th exon in thrombosis patients. In Figure 3 , analyses of PCR products of FVIII gene 19th exon thrombosis patients; patient (no 4) was found to have different pattern in SSCA gel analyses. According to the results of comparison studies, exon 6, exon 13, and exon 19 regions in which differences were detected in SSCA analyses, any mutation or variation in the samples could not be determined. However, comparisons on exon 14F and exon 25 regions some individuals with certain pattern, differences were detected. Individual numbered as 14 that shows differences in this region, sequences were analyzed Sanger ''Sanger Institute'' genome research from the Internet site of the FVIII gene cDNA sequence with ExPASy (Expert Protein Analysis System) protemics research on the Internet site ''Translate tool'' program with the help of comparison is performed, and the exchange found to occur 1288th codon. In 1288th codon changes, TCA sequence to TCC was observed. However, no chances in encoded amino acid occur, because they both code the serine amino acid. Change that we have caught 14F region of venous thrombosis patients (no 14) 1288th exon code A > C change does not reveal a difference in terms of the amino acids, similarly 25th exon region of venous thrombosis patients (no 9) 2288th exon code G > A change is not considered a factor to chances in terms of encoded amino acids and protein structure. Exon 14F region of individual (no 24) in venous thrombosis patients and individuals 23 and 34 healthy control group give the same pattern, C > G change at 1260th codon, resulting in changes encoded amino acid aspartic acid to glutamic acid is shown. No 23 and no 34 healthy control group individuals have the normal values of FVIII levels, for this reason the change of the FVIII protein structure is not considered a factor to be associated with an increase in activity.
Discussion
The development of thrombosis depends on complex interactions such as deficiencies in protein C, in protein S, in antithrombin, APC resistance, hyperhomocysteinemia, prothrombin 20210 allele, and high FVIII levels, at least 25% of cases with high FVIII levels. 2, 10 There are several studies focusing on the possible relationship among protein C, factor V Leiden (FV Leiden), prothrombin (FII) gene mutations, and thrombosis in Turkish patients with venous thrombosis. 13, 14 Altınısık et al 13 performed genotyping for FV Leiden, FII, and protein C mutations in 50 patients with thrombosis and 25 control participants. The study results indicated that patients with protein C deficiency had a greater risk of thrombosis than patients with FV or FII G20210A mutation. 13 Dolek et al 14 , was significantly associated with FVIII: C level. They also found a SNP 56010G>A, a SNP within the 3 0 splice junction of intron 7, is strongly associated with 92714C>G in GAIT; additional studies are required to determine whether D1241E is itself a functional variant. Both PCR and SSCA methods related to FVIII gene promoter region in both venous thrombosis patients and healthy control groups showed no differences in DNA patterns. In our experimental group, it was found that promoter region is not linked with high FVIII plasma levels. Similarly, according to the PCR and SSCA results, no pattern differences were observed at the APC cutting regions at exon 8/9 and exon 11 in FVIII gene, in the arginine 336 and 562 places between venous thrombosis patients and healthy control group. Earlier studies have suggested that thrombosis associated with inherited abnormalities of homeostasis typically presents at a young age (<40 years). 15 The mean age of the patient group and the control group were 23 + 17 and 49 + 12, respectively. Moreover, participants did not have any risk factors for thrombosis, such as myocardial infarction, diabetes mellitus, hypertension, or coronary heart disease. Although we only examined exon regions in a small population of patients group during our survey, we were able to observe common polymorphisms and variants including other contributing factors to thrombosis pathogenesis. Our findings could provide further data to wider scope studies in the future regarding risk factors and complex trait thrombosis.
